FY2025 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Analysts at Zacks Research raised their FY2025 earnings per share estimates for shares of Pfizer in a research note issued to investors on Tuesday, November 25th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $3.15 for the year, up from their prior forecast of $3.10. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q4 2025 earnings at $0.58 EPS, Q1 2026 earnings at $0.73 EPS, Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $0.68 EPS and Q3 2027 earnings at $1.00 EPS.

PFE has been the subject of several other reports. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.73 on Wednesday. The company’s fifty day moving average is $24.91 and its two-hundred day moving average is $24.54. The company has a market cap of $146.26 billion, a P/E ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. TCW Group Inc. increased its stake in Pfizer by 5.7% during the first quarter. TCW Group Inc. now owns 84,061 shares of the biopharmaceutical company’s stock valued at $2,130,000 after acquiring an additional 4,523 shares during the period. Mackenzie Financial Corp lifted its position in shares of Pfizer by 29.9% in the 1st quarter. Mackenzie Financial Corp now owns 844,463 shares of the biopharmaceutical company’s stock worth $21,399,000 after acquiring an additional 194,550 shares during the period. Finally, Norden Group LLC grew its holdings in shares of Pfizer by 3.4% during the 1st quarter. Norden Group LLC now owns 32,627 shares of the biopharmaceutical company’s stock worth $827,000 after purchasing an additional 1,065 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.